Back to journals
Academic JournalOpen Access

PLOS ONE

31 Papers Indexed in Blossom

Data updated

Publication Landscape

How the 31 psychedelic papers Blossom tracks from PLOS ONE line up by year, topic and compound. This is the journal's psychedelic-research output in Blossom's records as of July 2026; its full catalogue is much larger.

How much psychedelic research does PLOS ONE carry?

Sourced

Tracked papers by publication year. Click a year for the running total.

4papers published in 2022

+300% vs 2021

25 published by 2022

Browse papers→

Don't read as the journal's total output: only the 31 of 31 tracked psychedelic papers from PLOS ONE with a recorded publication date are counted, and Blossom tracks only psychedelic-relevant papers, so the full catalogue is much larger. The current year is still filling in.

What does PLOS ONE publish on?

Sourced

Tracked papers per topic. Orange marks the largest research focus.

Depressive Disorders
9
Anxiety Disorders
9
Addiction & Substance Use
8
PTSD
7
Neuroimaging & Brain Measures
5
Safety & Risk Management
4
Personality & Trait Factors
4
Neurocognitive Disorders
3
Other
22

Don't read shares as adding to 100%: a paper tagged with several topics counts once per topic. These are the psychedelic-relevant papers Blossom tracks, not the journal's full catalogue.

Which compounds does PLOS ONE cover?

Sourced

Tracked papers per compound. Orange marks the most-covered compound.

Psilocybin
9
Ayahuasca
8
MDMA
8
LSD
4
DMT
2
Ibogaine
1
5-MeO-DMT
1
Mescaline
1
Other
1

Don't read shares as adding to 100%: a paper studying several compounds counts once per compound, and placebo comparator arms are not shown. These are the psychedelic-relevant papers Blossom tracks.

Research Footprint

PLOS ONE has 31 tracked papers indexed in Blossom (2010–2024) from 168 authors, most often covering Psilocybin, Ayahuasca and MDMA, across Depressive Disorders, Anxiety Disorders and Substance Use Disorders (SUD).

Published Papers

Open Accessindividual

Cost-effectiveness of midomafetamine-assisted therapy (MDMA-AT) in chronic and treatment-resistant post-traumatic stress disorder of moderate or higher severity: A health-economic model

Using a health state-transition model, midomafetamine-assisted therapy for chronic, moderate-or-higher PTSD produced a 0.377 QALY gain over five years at an incremental cost of $31,613, yielding an ICER of $83,845 per QALY. These results indicate MDMA-AT is likely cost-effective versus placebo with therapy at a $150,000 willingness-to-pay threshold (assuming a $12,000 per-session drug price).

Published
Journal
PLOS ONE
Authors
Stanghellini, G.
Open Accessindividual

The therapeutic alliance between study participants and intervention facilitators is associated with acute effects and clinical outcomes in a psilocybin-assisted therapy trial for major depressive disorder

In a randomised, waiting‑list‑controlled psilocybin‑assisted therapy trial for major depressive disorder (N = 24), therapeutic alliance strengthened over time and higher alliance ratings before and shortly after dosing predicted stronger acute mystical and psychological‑insight experiences and significantly greater reductions in depressive symptoms up to 12 months. These results highlight the therapeutic relationship as an important predictor of both acute psychedelic experiences and long‑term clinical outcomes.

Published
Journal
PLOS ONE
Authors
Levin, A. W., Lancelotta, R., Sepeda, N. D., Gukasyan, N., Nayak, S., Wagener, T. L., Barrett, F. S., Griffiths, R. R., Davis, A. K.
Open Accessindividual

Effects of MDMA-assisted therapy for PTSD on self-experience

This re-analysis of an RCT of MDMA-assisted therapy for PTSD finds that study participants (n=90) had significant improvements in the measures of self-experience (e.g. alexithymia -; the inability to identify & describe emotions experienced by oneself). The change in scores of self-experience correlates with recovery from PTSD.

Published
Journal
PLOS ONE
Authors
van der Kolk, B., Wang, J. B., Yehuda, R., Bedrosian, L., Cooker, A., Harrison, C., Mithoefer, M. C., Emerson, A., Doblin, R., Yazar-Klosinski, B.
Open Accessindividual

Spiritual health practitioners’ contributions to psychedelic assisted therapy: A qualitative analysis

Interviews with 15 spiritual health practitioners identified seven themes—five unique contributions (competence with spiritual material, awareness of power dynamics, familiarity with non‑ordinary states, holding space, and a counterbalance to biomedical perspectives) and two general contributions (therapeutic repertoire and interdisciplinary collaboration)—showing they offer distinctive expertise to psychedelic‑assisted therapy. The authors conclude that teams may benefit from including spiritual health practitioners, but standardised role definitions, qualifications and training are needed to ensure quality and safety.

Published
Journal
PLOS ONE
Authors
Peacock, C., Mascaro, J. S., Brauer, E., Zarrabi, A. J., Dunlop, B. W., Maples-Keller, J. L., Grant, G. H., Raison, C. L., Rab, F., Palitsky, R.
Open Accessindividual

Extended difficulties following the use of psychedelic drugs: A mixed methods study

This mixed‑methods study of 608 people reporting extended difficulties after psychedelic use found common problems—anxiety and fear, existential struggle, social disconnection and depersonalisation/derealisation—with about one third affected for over a year and one sixth for more than three years. Shorter duration was associated with knowing the dose and drug type and with lower acute difficulty, while a narrower range of difficulties was linked to taking the drug in a guided setting, with implications for harm reduction.

Published
Journal
PLOS ONE
Authors
Evans, J., Robinson, O., Ketzitzidou-Argyri, E., Suseelan, S., Murphy-Beiner, A., McAlpine, R.
Open Accessindividual

LSD-induced increase of Ising temperature and algorithmic complexity of brain dynamics

Using pairwise maximum-entropy (Ising) models and algorithmic-complexity measures on fMRI from 15 subjects, the study shows that LSD raises individualized Ising temperatures, shifting brain dynamics further into an above-critical, more disordered (paramagnetic) regime. This shift is accompanied by reduced homotopic interhemispheric connectivity and increased algorithmic complexity (notably BDM), and the derived Ising archetypes correlate strongly with a structural connectome template (r ≈ 0.6).

Published
Journal
PLOS ONE
Authors
Ruffini, G., Damiani, G., Lozano-Soldevilla, D., Deco, N., Rosas, F. E., Kiani, N. A., Ponce-Alvarez, A., Kringelbach, M. L., Carhart-Harris, R., Deco, G.

Quick Facts

Papers Indexed
31
h-Index
467
Open Access
Yes
Publisher
Public Library of Science
Country
United States
Website
Visit